Oramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 USD | +1.79% | +10.14% | -1.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.30% | 92.63M | |
+34.01% | 51.07B | |
-8.02% | 38.78B | |
+35.28% | 38.86B | |
-11.12% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ORMP Stock
- News Oramed Pharmaceuticals Inc.
- Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes